FDA grants RMAT designation to RiboX’s RXRG001 for xerostomia

RegulatoryRXRG001Positive

AI Analysis

Summary

The FDA has granted RMAT (Regenerative Medicine Advanced Therapy) designation to RiboX Therapeutics' investigational drug RXRG001 for the treatment of xerostomia and hyposalivation, expediting its development pathway.

Outcome Details

RMAT designation granted

Importance:6/10

Sentiment:

0.70

RMAT designationFDAXerostomiaRare diseaseRegenerative medicine

Read the original article

Published by Pharmaceutical Technology on September 9, 2026 8:49 AM

Read Original